PT  - JOURNAL ARTICLE
AU  - Mihir R. Bakhru
AU  - Deepak L. Bhatt
TI  - Interpreting the Charisma Study
DP  - 2008 Apr 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 289--295
VI  - 75
IP  - 4
4099  - http://www.ccjm.org/content/75/4/289.short
4100  - http://www.ccjm.org/content/75/4/289.full
SO  - Cleve Clin J Med2008 Apr 01; 75
AB  - The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study (N Engl J Med 2006; 354:1706–1717, J Am Coll Cardiol 2007; 49:1982–1988) assessed the effect of dual antiplatelet therapy with clopidogrel (Plavix) and aspirin in patients at risk of atherothrombotic events. At a median of 28 months, the rate of the primary efficacy end point (a composite of myocardial infarction, stroke, and death from cardiovascular causes) was not significantly lower in the group receiving clopidogrel plus aspirin than in the group receiving placebo plus aspirin. However, one subgroup may have derived some benefit from the combination: those at higher risk owing to a history of myocardial infarction, ischemic stroke, or symptomatic peripheral arterial disease.